DNA Q4 2025 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M-23.8% YoY

Gross Profit

$42M124.4% margin

Operating Income

-$71M-211.9% margin

Net Income

-$81M-241.8% margin

EPS (Diluted)

$-1.43

QoQ Revenue Growth

-14.0%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$63M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$611M

Stockholders' Equity

$509M

Cash & Equivalents

$167M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$44M	-23.8%
Gross Profit	$42M	$34M	+21.4%
Operating Income	-$71M	-$104M	+31.7%
Net Income	-$81M	-$108M	+24.9%

Revenue Segments

Service

$17M100%